Evidence map›Paper›PMID 42577265›Full record

ArticleFrontiers in immunology2026

Novel pathogenic

Danping Zheng, Chunyang Tian, Xiaoqi Ye, Ziyin Ye, Gayatree Mohapatra, Haiyuan Ma, Baili Chen, Zhirong Zeng, Shenghong Zhang, Taofeng Jiang and 2 more

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Danping ZhengDepartment of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Chunyang TianDepartment of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Xiaoqi YeDepartment of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Ziyin YeDepartment of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Gayatree MohapatraDivision of Microbiome and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Haiyuan MaDepartment of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Baili ChenDepartment of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Zhirong ZengDepartment of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Shenghong ZhangDepartment of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Taofeng JiangDepartment of Gastroenterology, Meizhou People's Hospital, Meizhou Academy of Medical Sciences, Meizhou, China.
Yao HeDepartment of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Minhu ChenDepartment of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4) haploinsufficiency is a rare monogenic immunodysregulatory disorder that can affect multiple organ systems, leading to a combination of autoimmunity, immunodeficiency, and lymphoproliferation. It is caused by heterozygous germline mutations of Methods: We performed whole-exome sequencing on a patient with adolescent-onset autoimmune enteropathy, early-onset gastric malignancy and multisystem comorbidities, who was initially misdiagnosed with Crohn's disease and refractory to multiple biologics. Functional assays assessed CTLA4 dimerization and CD80/CD86 binding capacity. Peripheral blood immunophenotyping was conducted using CyTOF and flow cytometry. Intestinal histopathology was evaluated by immunohistochemistry. The patient subsequently received targeted therapy with abatacept. Results: A novel heterozygous missense variant in Conclusion: These findings identify p.Phe56Cys as a novel loss-of-function CTLA4 variant that disrupts protein dimerization and ligand binding, expanding the mechanistic understanding of CTLA4 haploinsufficiency and supporting genetic screening in patients with refractory autoimmune enteropathy and early-onset gastric malignancy.

Indexed as

CTLA-4 AntigenMutation, MissensePolyendocrinopathies, AutoimmuneAbataceptAdolescentFemaleHumansMaleAbataceptCTLA-4 AntigenCTLA4 protein, humanabataceptautoimmune enteropathyCTLA4 haploinsufficiencyprimary immunodeficienciesregulatory T cells

Identifiers

PMID42577265
PMCPMC13453822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.